文献速递中枢神经肿瘤放疗姑息放疗与转移瘤

磷脂酰肌醇-3-激酶突变与放射治疗脑转移瘤局部失败风险增加相关

Phosphatidylinositol-3-Kinase Mutations Are Associated With Increased Local Failure in Brain Metastases Treated With Radiation.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2018-03-29

该回顾性研究纳入259例接受放射治疗的脑转移瘤患者,评估PI3K突变与局部失败的关系。全脑放疗患者中PI3K突变者局部失败风险更高(HR 2.67,P<.001),1年累积局部失败率为50% vs 26%;立体定向放射外科病灶中PI3K突变与局部失败无统计学显著关联,但1年累积局部失败率11% vs 5%。

要点

  • 全脑放疗脑转移患者中,PI3K突变者局部失败风险显著升高(HR 2.67,P<.001)。
  • 全脑放疗后1年累积局部失败率:PI3K突变者50%(95%CI 32%-65%)vs 无突变者26%(95%CI 17%-37%)。
  • 立体定向放射外科病灶中PI3K突变与局部失败无统计学显著关联,1年累积局部失败率11% vs 5%。

核心结论

  • PI3K突变的脑转移瘤患者接受放射治疗后局部失败风险更高。
  • 作者认为应考虑新的治疗策略以改善这些患者的治疗结局。

研究设计与样本

  • 回顾性综述2004年至2017年间接受放射治疗的259例脑转移瘤患者,原发或转移病灶具有肿瘤遗传学数据(MSK-IMPACT)。
  • 112例接受全脑放疗,中位剂量30 Gy分10次;147例接受立体定向放射外科治疗338个病灶,其中276个病灶接受单次立体定向放射外科(中位剂量21 Gy),76个病灶接受3至5次立体定向放射外科(中位剂量30 Gy)。
  • 采用单因素和多因素竞争风险回归评估临床因素、PI3K突变状态与局部失败的关系。

主要发现

  • PI3K突变见于36例全脑放疗患者(32%)和44例立体定向放射外科患者(30%)。
  • 全脑放疗患者多因素分析中,PI3K突变与局部失败风险升高相关(HR 2.67,P<.001)。
  • 全脑放疗后1年累积局部失败率:PI3K突变患者50%(95%CI 32%-65%)vs 无PI3K突变患者26%(95%CI 17%-37%)。
  • 立体定向放射外科病灶中,PI3K突变阳性与局部失败无统计学显著关联,但观察到局部失败率更高:1年累积局部失败率PI3K突变患者11%(95%CI 6%-17%)vs 无PI3K突变患者5%(95%CI 3%-9%)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To determine whether phosphatidylinositol-3-kinase (PI3K) mutations confer suboptimal local control after radiation therapy (RT) for brain metastases. METHODS AND MATERIALS: We retrospectively reviewed 259 patients with brain metastases treated with RT during the period 2004 to 2017 for whom tumor genetic data (MSK-IMPACT) were available for primary or metastatic lesions. Associations between clinical factors, PI3K mutations status, and local failure (LF) were evaluated with univariate and multivariate competing risks regression. RESULTS: A total of 112 patients received whole brain radiation therapy (WBRT) to a median dose of 30 Gy in 10 fractions, and 147 patients received stereotactic radiosurgery (SRS) to 338 lesions; 276 lesions were treated with single fraction SRS (median dose 21 Gy) and 76 lesions over 3 to 5 fractions SRS (median dose 30 Gy). PI3K mutations were present in 36 WBRT patients (32%) and 44 SRS patients (30%). For WBRT, patients with PI3K mutations (hazard ratio 2.67, P < .001) were found to be at higher risk for LF on multivariable analysis, and the 1-year cumulative incidence of LF was 50% (95% confidence interval [CI] 32%-65%) for patients with PI3K mutations versus 26% (95% CI 17%-37%) for patients without PI3K mutations. For SRS lesions, while PI3K mutations positivity was not statistically significantly associated with LF, higher rate of LF was observed: 1-year LF cumulative incidence of 11% (95% CI 6%-17%) for patients with PI3K mutations versus 5% (95% CI 3%-9%) for patients without PI3K mutations. CONCLUSION: Patients with PI3K mutations are at higher risk for LF for brain metastases after RT. Novel therapeutic strategies to improve treatment outcomes in these patients should be considered.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Lockney NA, Wang DG, Pei X, et al. Phosphatidylinositol-3-Kinase Mutations Are Associated With Increased Local Failure in Brain Metastases Treated With Radiation. Int J Radiat Oncol Biol Phys. 2018. PMID: 29976496. doi:10.1016/j.ijrobp.2018.03.032

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。